星洲熱股評析
基本面持稳．柔医保股价明年料回调
2017-12-13 09:29
柔佛医药保健料在2018财政年营业额增长助攻下，股价在明年初将出现调整。
（吉隆坡12日讯）柔佛医药保健（KPJ，5878，主板贸服组）料在2018财政年营业额增长助攻下，股价在明年初将出现调整。
MIDF研究认为，柔佛医药保健股价在近期走软，而该公司在基本面维持稳健下，股价下滑是不合理的事情。
MIDF表示，预计在新医院开始作出贡献及现有医院表现步上轨道后，营业额贡献将能逐步走稳。
另外，柔佛医药保健于周一透过文告表示，将以1300万令吉，将旗下雪兰莪专科医院的5层停车场资产，脱售给ALSREIT产托（ALSREIT，5269，主板产业投资信托组），不过，办公室资产为了最大化享有投资税务减免，而暂时不会脱售。
MIDF预计，柔佛医药保健将在2018年开始，逐步注入旗下资产予ALSREIT产托，而上述办公室料在2022年始注入。
综合以上，MIDF上调柔佛医药保健至“买进”评级，和维持1令吉零6仙目标价。
文章来源：
星洲日报‧财经‧2017.12.13http://www.sinchew.com.my/node/1709994/基本面持稳．柔医保股价明年料回调
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
2024-07-18
KPJ2024-07-18
KPJ2024-07-18
KPJ2024-07-18
KPJ2024-07-17
KPJ2024-07-17
KPJ2024-07-17
KPJ2024-07-16
KPJ2024-07-16
KPJ2024-07-16
KPJ2024-07-16
KPJ2024-07-15
KPJ2024-07-15
KPJ2024-07-15
KPJ2024-07-15
KPJ2024-07-15
KPJ2024-07-12
KPJ2024-07-12
KPJ2024-07-12
KPJ2024-07-11
KPJ2024-07-11
KPJ2024-07-11
KPJ2024-07-11
KPJ2024-07-11
KPJ2024-07-10
KPJ2024-07-10
KPJ2024-07-09
KPJ2024-07-09
KPJ2024-07-09
KPJMore articles on 星洲熱股評析
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
.png)
MQ Trading Signals
Time
Signal
Duration
Type
2024-07-18 16:40:00
EMA 5
10 Mins
SELL
2024-07-18 16:40:00
OBV
10 Mins
SELL
2024-07-18 16:40:00
EMA 5
5 Mins
SELL
2024-07-18 16:30:00
OBV
30 Mins
SELL
2024-07-18 16:15:00
OBV
5 Mins
SELL
Apps
Top Articles
1
CEO Morning Brief
PGF Capital to Distribute Thermal Insulated Panels for Data Centres
3
Good Articles to Share
4
Rakuten Trade Research Reports
5
6
Bimb Research Highlights
7
The Alpha Trader
8
Chloe Tai Blog
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
